Company Focus
Teva Pharmaceutical Industries
Latest Teva Pharmaceutical Industries News
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its June 2025 meeting. 20 June 2025
Related News
Insights
Company Spotlight
An American biotech company developing solutions that treat urothelial and specialty cancers.
Latest News & Features of interest to Teva Pharmaceutical Industries
Biotechnology
Switzerland-based Philochem and Bristol Myers Squibb radiopharma subsidiary RayzeBio have announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. 11 June 2025
Biotechnology
US clinical-stage biotech Oncolytics Biotech today announced the appointment of Jared Kelly as chief executive (CEO) and a member of its board of directors. 11 June 2025
Pharmaceutical
USA-based Insmed Incorporated closed Tuesday’s trading up by more than a third. 11 June 2025
Biotechnology
South Korean biotech AriBio Co, specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi, announced an exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease. 11 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Biotechnology
Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. 11 June 2025
Pharmaceutical
UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO). 10 June 2025
Biotechnology
June 10, 2025
The US Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season, US pharma giant Merck & Co revealed yesterday. 10 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 10 June 2025
Biotechnology
Dutch late-stage biotech NewAmsterdam Pharma late yesterday announced positive top-line data from prespecified Alzheimer’s disease (AD) biomarker analyses in the Phase III BROADWAY clinical trial (NCT05142722). The firm’s US-traded shares were up 4.1% at $20.99 in pre-market activity this morning. 10 June 2025
Latest In Brief for Teva Pharmaceutical Industries
Biosimilars
The European Medicines Agency’s human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its June meeting. 20 June 2025
Latest Relevant Ones To Watch News
Supernus Pharmaceuticals is to buy Sage Therapeutics for total consideration of around $795 million. 16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze